These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16766095)

  • 1. Transcutaneous immunization with inactivated influenza virus induces protective immune responses.
    Skountzou I; Quan FS; Jacob J; Compans RW; Kang SM
    Vaccine; 2006 Aug; 24(35-36):6110-9. PubMed ID: 16766095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P; Havlícková M; Tácner J; Novotná O; Jirkovská M; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2008 Jan; 115(2):144-52. PubMed ID: 18160106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
    Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
    Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against influenza infection by cytokine-enhanced aerosol genetic immunization.
    Orson FM; Kinsey BM; Densmore CL; Nguyen T; Wu Y; Mbawuike IN; Wyde PR
    J Gene Med; 2006 Apr; 8(4):488-97. PubMed ID: 16389596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL
    Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of resistance to influenza virus infection in animal models.
    Potter CW; McLaren C; Jennings R
    Dev Biol Stand; 1975; 28():307-18. PubMed ID: 1126574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
    Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
    Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.